Merck Keytruda granted full approval for certain tumor types
Sundry Photography/iStock Editorial via Getty Images
- The US FDA has converted to full approval to Merck's (NYSE:MRK) Keytruda (pembrolizumab) for adults and children with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors.
- The conversion from an accelerated approval from three phase 2 trials of more than 500 adult and pediatric patients including more than 30 cancer types.
- Merck (MRK) said the approval is the first full approval of an immunotherapy based on a predictive biomarker, regardless of tumor type.
- See why Seeking Alpha contributor Cory Cramer rates Merck (MRK) a hold.